特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
969427

ポイントオブケア (POC) 検査の業界分析レポート:製品・技術・処方・アプリケーション・エンドユーズ・地域展望・アプリケーション可能性・価格動向・競合市場シェア & 予測 (2020-2026年)

Point of Care Testing Market Size By Product, By Technology, By Prescription, By Application, By End-use, Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2020 - 2026

出版日: | 発行: Global Market Insights Inc. | ページ情報: 英文 400 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
ポイントオブケア (POC) 検査の業界分析レポート:製品・技術・処方・アプリケーション・エンドユーズ・地域展望・アプリケーション可能性・価格動向・競合市場シェア & 予測 (2020-2026年)
出版日: 2020年11月05日
発行: Global Market Insights Inc.
ページ情報: 英文 400 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 目次
概要

世界におけるポイントオブケア (POC) 検査市場は、ヘルスケアおよび医療機器です分野で最も重要な垂直市場のひとつであり、今後数年間で大幅な成長が見込まれています。世界的な慢性疾患の発生率および高齢者人口の急増により、高度な診断手法・技術の必要性が高まっています。

当レポートでは、世界のポイントオブケア (POC) 検査市場について調査分析し、市場の概要、各セグメント・地域別の市場動向、市場規模の推移と予測、市場促進要因および阻害要因の分析、市場の将来展望、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

目次

第1章 調査手法と範囲

  • 市場の定義
  • 市場の見積もりと予測パラメータ
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東とアフリカ
  • 予測パラメータ
  • データ検証
  • データソース
    • 一次
    • 二次

第2章 エグゼクティブサマリー

  • ポイントオブケア (POC) 検査市場の全方位的概要
    • ビジネス動向
    • 製品動向
    • 技術動向
    • 処方動向
    • アプリケーション動向
    • エンドユーズ動向
    • 地域動向

第3章 ポイントオブケア (POC) 検査業界の考察

  • 業界セグメンテーション
  • 業界情勢
  • 業界への影響要因
    • 成長要因
    • 業界の潜在的リスク&課題
  • 成長可能性の分析
    • 製品別
    • 技術別
    • 処方別
    • アプリケーション別
    • エンドユーズ別
  • COVID-19の影響分析
  • 価格分析:心臓マーカー別
  • 規制状況
  • 技術情勢
  • 企業シェア分析
    • 世界の市場シェア分析
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東とアフリカ
  • 世界の市場シェア分析:設定・アプリケーション別
  • 企業の世界市場シェア分析:設定・アプリケーション別
    • F. Hoffmann-La Roche Ltd
    • Abbott
    • Johnson and Johnson
    • Siemens AG
    • Abaxis
  • ポーターの分析
  • 競合情勢
    • 企業のマトリックス分析
  • PESTEL分析

第4章 ポイントオブケア (POC) 検査市場:製品別

  • 主要なセグメントの動向
  • グルコースモニタリング
    • 市場規模:地域別
    • ストリップ
    • 計量器
    • ランセット
  • 心血管代謝検査製品
    • 市場規模:地域別
    • 心臓マーカー検査製品
    • 血液ガス/電解質検査製品
    • HBA1Cテスト製品
  • 感染症検査製品
    • 市場規模:地域別
    • インフルエンザ検査製品
    • HIV検査製品
    • C型肝炎検査製品
    • 性感染症(STD)検査製品
    • 医療関連感染(HAI)検査製品
    • 呼吸器感染症検査製品
    • 熱帯病検査製品
    • その他の感染症検査製品
  • 凝固検査製品
    • 市場規模:地域別
    • PT / INRテスト製品
    • 活性化凝固時間(ACT / APTT)テスト製品
  • 妊娠および不妊検査製品
    • 市場規模:地域別
    • 妊娠検査製品
    • 不妊検査製品
  • 腫瘍/がんマーカー検査製品
  • 尿検査検査製品
  • コレステロール検査製品
  • 血液検査製品
  • 薬物乱用(DoA)テスト製品
  • 便潜伏検査製品
  • その他の商品

第5章 ポイントオブケア (POC) 検査市場:技術別

  • 主要セグメントのトレンド
  • ラテラルフローアッセイ
    • 市場規模:地域別
  • ディップスティック
  • マイクロフルイディクス
  • 分子診断
  • 免疫学的検査
  • 凝集アッセイ
  • フロースルー
  • 固相
  • バイオセンサー

第6章 ポイントオブケア (POC) 検査市場:処方別

  • 主要セグメントのトレンド
  • OTC検査
    • 市場規模:地域別
  • 処方ベース検査

第7章 ポイントオブケア (POC) 検査市場:アプリケーション別

  • 主要セグメントのトレンド
  • 心血管代謝検査
    • 市場規模:地域別
  • 感染症検査
  • 腎臓検査
  • 薬物乱用(DoA)テスト
  • 血糖値検査
  • 妊娠検査
  • がんバイオマーカー検査
  • その他のアプリケーション

第8章 ポイントオブケア (POC) 検査市場:エンドユーズ別

  • 主要セグメントのトレンド
  • 病院
    • 市場規模:地域別
  • 診断センター
  • 研究
  • 在宅医療
  • その他

第9章 ポイントオブケア (POC) 検査市場:地域別

  • 主な地域の動向
  • 北米
    • 市場規模:国別
    • 市場規模:製品別
    • 市場規模:技術別
    • 市場規模:処方別
    • 市場規模:アプリケーション別
    • 市場規模:エンドユーズ別
    • 米国
    • カナダ
  • 欧州
    • 市場規模:国別
    • 市場規模:製品別
    • 市場規模:技術別
    • 市場規模:処方別
    • 市場規模:アプリケーション別
    • 市場規模:エンドユーズ別
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
  • アジア太平洋
    • 市場規模:国別
    • 市場規模:製品別
    • 市場規模:技術別
    • 市場規模:処方別
    • 市場規模:アプリケーション別
    • 市場規模:エンドユーズ別
    • 中国
    • 日本
    • インド
    • オーストラリア
  • ラテンアメリカ
    • 市場規模:国別
    • 市場規模:製品別
    • 市場規模:技術別
    • 市場規模:処方別
    • 市場規模:アプリケーション別
    • 市場規模:エンドユーズ別
    • ブラジル
    • メキシコ
  • 中東とアフリカ
    • 市場規模:国別
    • 市場規模:製品別
    • 市場規模:技術別
    • 市場規模:処方別
    • 市場規模:アプリケーション別
    • 市場規模:エンドユーズ別
    • 南アフリカ
    • サウジアラビア

第10章 企業プロファイル

  • Abaxis, Inc.
  • Abbott Laboratories
  • Accubiotech Co, Ltd.
  • ACON Laboratories, Inc.
  • Becton, Dickinson and Company
  • Biolytical Laboratories
  • BioMrieux SA
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation (HemoCue)
  • Dexcom, Inc
  • Dragerwerk Ag & Co
  • LifeScan IP Holdings, LLC
  • Medtronic
  • Meridian Bioscience, Inc
  • Nova Biomedical
  • Orasure Technologies, Inc
  • F Hoffmann-La Roche Ltd
  • Siemens Healthineers
  • Sysmex Corporation
  • Trinity Biotech
目次
Product Code: 3086

Title:
Point of Care Testing Market Size By Product (Glucose Monitoring, Cardiometabolic Testing, Infectious Disease Testing, Coagulation Testing, Pregnancy and Fertility Testing, Tumor/Cancer Marker Testing, Urinalysis Testing, Cholesterol Testing, Hematology Testing, Drugs-of-Abuse Testing, Fecal Occult Testing), By Technology (Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics, Immunoassays, Agglutination Assays, Flow-Through, Solid Phase, Biosensors), By Prescription (OTC Testing, Prescription-based Testing), By Application (Cardio Metabolic Testing, Infectious Disease Testing, Nephrology Testing, Drug-of-Abuse (DoA) Testing, Blood Glucose Testing, Pregnancy Testing, Cancer Biomarker Testing), By End-use (Hospitals, Diagnostic Centers, Research Laboratories, Home-Care Settings), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2020 - 2026.

One of the most crucial verticals within the healthcare and medical devices space, global point of care testing market is slated to witness exponential growth over the next few years. The rapid increase in occurrence of chronic diseases and a large geriatric population across the globe has augmented the need for advanced diagnostic procedures and technologies.

In terms of the product landscape, global point of care testing industry is segmented into glucose monitoring, infectious diseases testing products, cardiometabolic testing products, coagulation testing products, tumor & cancer marker testing products, pregnancy & fertility testing products, drug-of-abuse testing products, hematology testing products, and cholesterol testing products.

Cardiometabolic testing market size was pegged at USD 2.5 billion in 2019. The test provides a clinically relevant evaluation to help identify a patient's risk for cardiovascular inflammation, progression towards type 2 diabetes (pre-diabetes), and atherosclerotic cardiovascular disease (ASCVD).

Considering the technology, global point of care testing market is bifurcated into lateral flow assays, biosensors, dipsticks, flow-through, microfluidics, immunoassays, molecular diagnostics, agglutination assays, and solid phase. The biosensors technology segment is projected to be worth more than US$11.8 billion by 2026.

On the basis of prescription, global point of care testing industry is divided into OTC testing and prescription based testing. The prescription based testing segment is poised to grow at a CAGR of over 7.4% through 2026.

The market is classified into cardiometabolic testing, nephrology testing, infectious disease testing, blood glucose testing, drug-of-abuse testing, cancer biomarker testing, and pregnancy testing based on applications. Blood glucose testing application segment accounted for more than 42.2% revenue share of global point of care testing market during 2019 and is likely to witness notable growth by 2026.

Blood glucose testing is an important procedure that measures glucose levels in the blood. Glucose is a type of sugar which is the main source of energy for the human body. Too little or too much glucose in the blood can lead to numerous critical conditions and complications. High blood glucose levels, also known as hyperglycemia, can indicate diabetes that can further increase the risk of heart diseases, kidney failure, blindness, and other complications. On the other hand, low blood glucose levels or hypoglycemia can cause major health problems such as brain damage.

Hospitals, research laboratories, diagnostic centers, and homecare settings are among the different end-users of point of care testing products. Global point of care testing industry size from home care settings is estimated to reach an annual valuation of over US$10.1 billion by 2026. This can be attributed to growing adoption of different diagnostic and testing products among consumers in homecare settings due to convenience and ease-of-use.

From a regional point of view, Latin America captured over 5.6% revenue share of global point of care market testing in 2019 and will grow substantially by 2026. The point of care testing industry in Middle East and Africa is likely to witness a healthy CAGR of nearly 7.7% through the same period.

Table of Contents

Chapter 1 Methodology

  • 1.1 Market definitions
  • 1.2 Base estimates & working
    • 1.2.1 North America
    • 1.2.2 Europe
    • 1.2.3 Asia Pacific
    • 1.2.4 Latin America
    • 1.2.5 Middle East & Africa
  • 1.3 Forecast parameters
  • 1.4 Data validation
  • 1.5 Data Sources
    • 1.5.1 Secondary
      • 1.5.1.1 Paid sources
      • 1.5.1.2 Unpaid sources
    • 1.5.2 Primary

Chapter 2 Executive Summary

  • 2.1 Point of care testing industry 360 degree synopsis, 2015-2026
    • 2.1.1 Business trends
    • 2.1.2 Product trends
    • 2.1.3 Technology trends
    • 2.1.4 Prescription trends
    • 2.1.5 Application trends
    • 2.1.6 End-use trends
    • 2.1.7 Regional trends

Chapter 3 Point of Care Testing Industry Insights

  • 3.1 Industry segmentation
  • 3.2 Industry landscape, 2015 - 2026
  • 3.3 Industry impact forces
    • 3.3.1 Growth drivers
      • 3.3.1.1 Upward trend in disease prevalence among developing countries
      • 3.3.1.2 Surging number of pathology labs and services equipped with advanced diagnostic equipment in North America
      • 3.3.1.3 Technological advancements
      • 3.3.1.4 Increasing R&D investment
      • 3.3.1.5 Growing geriatric population base globally
    • 3.3.2 Industry pitfalls & challenges
      • 3.3.2.1 High cost of product development
  • 3.4 Growth potential analysis
    • 3.4.1 By product
    • 3.4.2 By technology
    • 3.4.3 By prescription
    • 3.4.4 By application
    • 3.4.5 By end-use
  • 3.5 COVID-19 impact analysis
  • 3.6 Pricing analysis, by cardiac markers, 2019
  • 3.7 Regulatory landscape
  • 3.8 Technology landscape
  • 3.9 Company share analysis, 2019
    • 3.9.1 Global market share analysis, 2019
    • 3.9.2 North America
    • 3.9.3 Europe
    • 3.9.4 Asia Pacific
    • 3.9.5 Latin America
    • 3.9.6 Middle East and Africa
  • 3.10 Global market share analysis, by settings and application, 2019
  • 3.11 Company global market share analysis, by setting and application, 2019
    • 3.11.1 F. Hoffmann-La Roche Ltd
    • 3.11.2 Abbott
    • 3.11.3 Johnson and Johnson
    • 3.11.4 Siemens AG
    • 3.11.5 Abaxis
  • 3.12 Porter's analysis
  • 3.13 Competitive landscape, 2019
    • 3.13.1 Company matrix analysis
  • 3.14 PESTEL analysis

Chapter 4 Point of Care Testing Market, By Product

  • 4.1 Key segment trends
  • 4.2 Glucose monitoring
    • 4.2.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.2.2 Strips
      • 4.2.2.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.2.3 Meters
      • 4.2.3.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.2.4 Lancets
      • 4.2.4.1 Market size, by region, 2015 - 2026 (USD Million)
  • 4.3 Cardiometabolic testing products
    • 4.3.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.3.2 Cardiac marker testing products
      • 4.3.2.1 Market size, by region, 2015 - 2026 (USD Million)
      • 4.3.2.2 High-sensitivity troponin I (hsTnl)
        • 4.3.2.2.1 Market size, by region, 2015 - 2026 (USD Million)
      • 4.3.2.3 Brain natriuretic peptide (BNP)
        • 4.3.2.3.1 Market size, by region, 2015 - 2026 (USD Million)
      • 4.3.2.4 D-dimer
        • 4.3.2.4.1 Market size, by region, 2015 - 2026 (USD Million)
      • 4.3.2.5 Creatine kinase-MB (CK-MB)
        • 4.3.2.5.1 Market size, by region, 2015 - 2026 (USD Million)
      • 4.3.2.6 Myoglobin
        • 4.3.2.6.1 Market size, by region, 2015 - 2026 (USD Million)
      • 4.3.2.7 Others
        • 4.3.2.7.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.3.3 Blood Gas/Electrolytes testing products
      • 4.3.3.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.3.4 HBA1C testing products
      • 4.3.4.1 Market size, by region, 2015 - 2026 (USD Million)
  • 4.4 Infectious disease testing products
    • 4.4.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.4.2 Influenza testing products
      • 4.4.2.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.4.3 HIV testing products
      • 4.4.3.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.4.4 Hepatitis C testing products
      • 4.4.4.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.4.5 Sexually transmitted disease (STD) testing products
      • 4.4.5.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.4.6 Healthcare-associated Infection (HAI) testing products
      • 4.4.6.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.4.7 Respiratory infection testing products
      • 4.4.7.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.4.8 Tropical disease testing products
      • 4.4.8.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.4.9 Other infectious diseases testing products
      • 4.4.9.1 Market size, by region, 2015 - 2026 (USD Million)
  • 4.5 Coagulation testing products
    • 4.5.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.5.2 PT/INR testing products
      • 4.5.2.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.5.3 Activated clotting time (ACT/APTT) testing products
      • 4.5.3.1 Market size, by region, 2015 - 2026 (USD Million)
  • 4.6 Pregnancy and fertility testing products
    • 4.6.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.6.2 Pregnancy testing products
      • 4.6.2.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.6.3 Fertility testing products
      • 4.6.3.1 Market size, by region, 2015 - 2026 (USD Million)
  • 4.7 Tumor/Cancer marker testing products
    • 4.7.1 Market size, by region, 2015 - 2026 (USD Million)
  • 4.8 Urinalysis testing products
    • 4.8.1 Market size, by region, 2015 - 2026 (USD Million)
  • 4.9 Cholesterol testing products
    • 4.9.1 Market size, by region, 2015 - 2026 (USD Million)
  • 4.10 Hematology testing products
    • 4.10.1 Market size, by region, 2015 - 2026 (USD Million)
  • 4.11 Drug-of-Abuse (DoA) testing products
    • 4.11.1 Market size, by region, 2015 - 2026 (USD Million)
  • 4.12 Fecal occult testing products
    • 4.12.1 Market size, by region, 2015 - 2026 (USD Million)
  • 4.13 Other products
    • 4.13.1 Market size, by region, 2015 - 2026 (USD Million)

Chapter 5 Point of Care Testing Market, By Technology

  • 5.1 Key segment trend
  • 5.2 Lateral flow assays
    • 5.2.1 Market size, by region, 2015 - 2026 (USD Million)
  • 5.3 Dipsticks
    • 5.3.1 Market size, by region, 2015 - 2026 (USD Million)
  • 5.4 Microfluidics
    • 5.4.1 Market size, by region, 2015 - 2026 (USD Million)
  • 5.5 Molecular diagnostics
    • 5.5.1 Market size, by region, 2015 - 2026 (USD Million)
  • 5.6 Immunoassays
    • 5.6.1 Market size, by region, 2015 - 2026 (USD Million)
  • 5.7 Agglutination assays
    • 5.7.1 Market size, by region, 2015 - 2026 (USD Million)
  • 5.8 Flow-Through
    • 5.8.1 Market size, by region, 2015 - 2026 (USD Million)
  • 5.9 Solid phase
    • 5.9.1 Market size, by region, 2015 - 2026 (USD Million)
  • 5.10 Biosensors
    • 5.10.1 Market size, by region, 2015 - 2026 (USD Million)

Chapter 6 Point of Care Testing Market, By Prescription

  • 6.1 Key segment trend
  • 6.2 OTC testing
    • 6.2.1 Market size, by region, 2015 - 2026 (USD Million)
  • 6.3 Prescription-based testing
    • 6.3.1 Market size, by region, 2015 - 2026 (USD Million)

Chapter 7 Point of Care Testing Market, By Application

  • 7.1 Key segment trend
  • 7.2 Cardio metabolic testing
    • 7.2.1 Market size, by region, 2015 - 2026 (USD Million)
  • 7.3 Infectious disease testing
    • 7.3.1 Market size, by region, 2015 - 2026 (USD Million)
  • 7.4 Nephrology testing
    • 7.4.1 Market size, by region, 2015 - 2026 (USD Million)
  • 7.5 Drug-of-Abuse (DoA) testing
    • 7.5.1 Market size, by region, 2015 - 2026 (USD Million)
  • 7.6 Blood glucose testing
    • 7.6.1 Market size, by region, 2015 - 2026 (USD Million)
  • 7.7 Pregnancy testing
    • 7.7.1 Market size, by region, 2015 - 2026 (USD Million)
  • 7.8 Cancer biomarker testing
    • 7.8.1 Market size, by region, 2015 - 2026 (USD Million)
  • 7.9 Other applications
    • 7.9.1 Market size, by region, 2015 - 2026 (USD Million)

Chapter 8 Point of Care Testing Market, By End-use

  • 8.1 Key segment trend
  • 8.2 Hospitals
    • 8.2.1 Market size, by region, 2015 - 2026 (USD Million)
  • 8.3 Diagnostic centers
    • 8.3.1 Market size, by region, 2015 - 2026 (USD Million)
  • 8.4 Research laboratories
    • 8.4.1 Market size, by region, 2015 - 2026 (USD Million)
  • 8.5 Home-care settings
    • 8.5.1 Market size, by region, 2015 - 2026 (USD Million)
  • 8.6 Others
    • 8.6.1 Market size, by region, 2015 - 2026 (USD Million)

Chapter 9 Point of Care Testing Market, By Region

  • 9.1 Key regional trends
  • 9.2 North America
    • 9.2.1 Market size, by country, 2015 - 2026 (USD Million)
    • 9.2.2 Market size, by product, 2015 - 2026 (USD Million)
      • 9.2.2.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
      • 9.2.2.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
      • 9.2.2.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
      • 9.2.2.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
      • 9.2.2.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
    • 9.2.3 Market size, by technology, 2015 - 2026 (USD Million)
    • 9.2.4 Market size, by prescription, 2015 - 2026 (USD Million)
    • 9.2.5 Market size, by application, 2015 - 2026 (USD Million)
    • 9.2.6 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.2.7 U.S.
      • 9.2.7.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.2.7.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.2.7.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.2.7.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.2.7.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.2.7.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.2.7.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.2.7.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.2.7.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.2.7.5 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.2.8 Canada
      • 9.2.8.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.2.8.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.2.8.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.2.8.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.2.8.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.2.8.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.2.8.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.2.8.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.2.8.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.2.8.5 Market size, by end-use, 2015 - 2026 (USD Million)
  • 9.3 Europe
    • 9.3.1 Market size, by country, 2015 - 2026 (USD Million)
    • 9.3.2 Market size, by product, 2015 - 2026 (USD Million)
      • 9.3.2.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
      • 9.3.2.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
      • 9.3.2.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
      • 9.3.2.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
      • 9.3.2.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
    • 9.3.3 Market size, by technology, 2015 - 2026 (USD Million)
    • 9.3.4 Market size, by prescription, 2015 - 2026 (USD Million)
    • 9.3.5 Market size, by application, 2015 - 2026 (USD Million)
    • 9.3.6 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.3.7 Germany
      • 9.3.7.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.3.7.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.3.7.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.3.7.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.3.7.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.3.7.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.3.7.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.3.7.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.3.7.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.3.7.5 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.3.8 UK
      • 9.3.8.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.3.8.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.3.8.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.3.8.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.3.8.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.3.8.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.3.8.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.3.8.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.3.8.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.3.8.5 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.3.9 France
      • 9.3.9.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.3.9.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.3.9.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.3.9.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.3.9.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.3.9.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.3.9.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.3.9.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.3.9.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.3.9.5 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.3.10 Spain
      • 9.3.10.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.3.10.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.3.10.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.3.10.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.3.10.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.3.10.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.3.10.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.3.10.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.3.10.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.3.10.5 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.3.11 Italy
      • 9.3.11.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.3.11.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.3.11.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.3.11.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.3.11.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.3.11.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.3.11.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.3.11.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.3.11.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.3.11.5 Market size, by end-use, 2015 - 2026 (USD Million)
  • 9.4 Asia Pacific
    • 9.4.1 Market size, by country, 2015 - 2026 (USD Million)
    • 9.4.2 Market size, by product, 2015 - 2026 (USD Million)
      • 9.4.2.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
      • 9.4.2.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
      • 9.4.2.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
      • 9.4.2.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
      • 9.4.2.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
    • 9.4.3 Market size, by technology, 2015 - 2026 (USD Million)
    • 9.4.4 Market size, by prescription, 2015 - 2026 (USD Million)
    • 9.4.5 Market size, by application, 2015 - 2026 (USD Million)
    • 9.4.6 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.4.7 China
      • 9.4.7.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.4.7.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.4.7.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.4.7.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.4.7.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.4.7.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.4.7.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.4.7.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.4.7.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.4.7.5 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.4.8 Japan
      • 9.4.8.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.4.8.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.4.8.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.4.8.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.4.8.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.4.8.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.4.8.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.4.8.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.4.8.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.4.8.5 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.4.9 India
      • 9.4.9.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.4.9.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.4.9.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.4.9.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.4.9.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.4.9.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.4.9.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.4.9.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.4.9.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.4.9.5 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.4.10 Australia
      • 9.4.10.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.4.10.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.4.10.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.4.10.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.4.10.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.4.10.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.4.10.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.4.10.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.4.10.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.4.10.5 Market size, by end-use, 2015 - 2026 (USD Million)
  • 9.5 Latin America
    • 9.5.1 Market size, by country, 2015 - 2026 (USD Million)
    • 9.5.2 Market size, by product, 2015 - 2026 (USD Million)
      • 9.5.2.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
      • 9.5.2.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
      • 9.5.2.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
      • 9.5.2.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
      • 9.5.2.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
    • 9.5.3 Market size, by technology, 2015 - 2026 (USD Million)
    • 9.5.4 Market size, by prescription, 2015 - 2026 (USD Million)
    • 9.5.5 Market size, by application, 2015 - 2026 (USD Million)
    • 9.5.6 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.5.7 Brazil
      • 9.5.7.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.5.7.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.5.7.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.5.7.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.5.7.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.5.7.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.5.7.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.5.7.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.5.7.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.5.7.5 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.5.8 Mexico
      • 9.5.8.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.5.8.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.5.8.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.5.8.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.5.8.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.5.8.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.5.8.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.5.8.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.5.8.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.5.8.5 Market size, by end-use, 2015 - 2026 (USD Million)
  • 9.6 Middle East and Africa
    • 9.6.1 Market size, by country, 2015 - 2026 (USD Million)
    • 9.6.2 Market size, by product, 2015 - 2026 (USD Million)
      • 9.6.2.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
      • 9.6.2.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
      • 9.6.2.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
      • 9.6.2.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
      • 9.6.2.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
    • 9.6.3 Market size, by technology, 2015 - 2026 (USD Million)
    • 9.6.4 Market size, by prescription, 2015 - 2026 (USD Million)
    • 9.6.5 Market size, by application, 2015 - 2026 (USD Million)
    • 9.6.6 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.6.7 South Africa
      • 9.6.7.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.6.7.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.6.7.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.6.7.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.6.7.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.6.7.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.6.7.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.6.7.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.6.7.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.6.7.5 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.6.8 Saudi Arabia
      • 9.6.8.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.6.8.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.6.8.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.6.8.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.6.8.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.6.8.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.6.8.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.6.8.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.6.8.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.6.8.5 Market size, by end-use, 2015 - 2026 (USD Million)

Chapter 10 Company Profiles

  • 10.1 Competitive dashboard
  • 10.2 Abaxis, Inc.
    • 10.2.1 Business overview
    • 10.2.2 Financial data
    • 10.2.3 Product landscape
    • 10.2.4 Strategic outlook
    • 10.2.5 SWOT analysis
  • 10.3 Abbott Laboratories
    • 10.3.1 Business overview
    • 10.3.2 Financial data
    • 10.3.3 Product landscape
    • 10.3.4 Strategic outlook
    • 10.3.5 SWOT analysis
  • 10.4 Accubiotech Co, Ltd.
    • 10.4.1 Business overview
    • 10.4.2 Financial data
    • 10.4.3 Product landscape
    • 10.4.4 Strategic outlook
    • 10.4.5 SWOT analysis
  • 10.5 ACON Laboratories, Inc.
    • 10.5.1 Business overview
    • 10.5.2 Financial data
    • 10.5.3 Product landscape
    • 10.5.4 Strategic outlook
    • 10.5.5 SWOT analysis
  • 10.6 Becton, Dickinson and Company
    • 10.6.1 Business overview
    • 10.6.2 Financial data
    • 10.6.3 Product landscape
    • 10.6.4 Strategic outlook
    • 10.6.5 SWOT analysis
  • 10.7 Biolytical Laboratories
    • 10.7.1 Business overview
    • 10.7.2 Financial data
    • 10.7.3 Product landscape
    • 10.7.4 Strategic outlook
    • 10.7.5 SWOT analysis
  • 10.8 BioMrieux SA
    • 10.8.1 Business overview
    • 10.8.2 Financial data
    • 10.8.3 Product landscape
    • 10.8.4 Strategic outlook
    • 10.8.5 SWOT analysis
  • 10.9 Bio-Rad Laboratories, Inc.
    • 10.9.1 Business overview
    • 10.9.2 Financial data
    • 10.9.3 Product landscape
    • 10.9.4 Strategic outlook
    • 10.9.5 SWOT analysis
  • 10.10 Danaher Corporation (HemoCue)
    • 10.10.1 Business overview
    • 10.10.2 Financial data
    • 10.10.3 Product landscape
    • 10.10.4 Strategic outlook
    • 10.10.5 SWOT analysis
  • 10.11 Dexcom, Inc
    • 10.11.1 Business overview
    • 10.11.2 Financial data
    • 10.11.3 Product landscape
    • 10.11.4 Strategic outlook
    • 10.11.5 SWOT analysis
  • 10.12 Dragerwerk Ag & Co
    • 10.12.1 Business overview
    • 10.12.2 Financial data
    • 10.12.3 Product landscape
    • 10.12.4 Strategic outlook
    • 10.12.5 SWOT analysis
  • 10.13 LifeScan IP Holdings, LLC
    • 10.13.1 Business overview
    • 10.13.2 Financial data
    • 10.13.3 Product landscape
    • 10.13.4 Strategic outlook
    • 10.13.5 SWOT analysis
  • 10.14 Medtronic
    • 10.14.1 Business overview
    • 10.14.2 Financial data
    • 10.14.3 Product landscape
    • 10.14.4 Strategic outlook
    • 10.14.5 SWOT analysis
  • 10.15 Meridian Bioscience, Inc
    • 10.15.1 Business overview
    • 10.15.2 Financial data
    • 10.15.3 Product landscape
    • 10.15.4 Strategic outlook
    • 10.15.5 SWOT analysis
  • 10.16 Nova Biomedical
    • 10.16.1 Business overview
    • 10.16.2 Financial data
    • 10.16.3 Product landscape
    • 10.16.4 Strategic outlook
    • 10.16.5 SWOT analysis
  • 10.17 Orasure Technologies, Inc
    • 10.17.1 Business overview
    • 10.17.2 Financial data
    • 10.17.3 Product landscape
    • 10.17.4 Strategic outlook
    • 10.17.5 SWOT analysis
  • 10.18 F Hoffmann-La Roche Ltd
    • 10.18.1 Business overview
    • 10.18.2 Financial data
    • 10.18.3 Product landscape
    • 10.18.4 Strategic outlook
    • 10.18.5 SWOT analysis
  • 10.19 Siemens Healthineers
    • 10.19.1 Business overview
    • 10.19.2 Financial data
    • 10.19.3 Product landscape
    • 10.19.4 Strategic outlook
    • 10.19.5 SWOT analysis
  • 10.20 Sysmex Corporation
    • 10.20.1 Business overview
    • 10.20.2 Financial data
    • 10.20.3 Product landscape
    • 10.20.4 Strategic outlook
    • 10.20.5 SWOT analysis
  • 10.21 Trinity Biotech
    • 10.21.1 Business overview
    • 10.21.2 Financial data
    • 10.21.3 Product landscape
    • 10.21.4 Strategic outlook
    • 10.21.5 SWOT analysis
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.